Evidence map›Paper›PMID 31973599›Full record

Trial reportJournal of the American Heart Association2020

Cluster-Randomized Trial of Thrombolysis Implementation Support in Metropolitan and Regional Australian Stroke Centers: Lessons for Individual and Systems Behavior Change.

Christopher R Levi, John A Attia, Cate D'Este, Annika E Ryan, Frans Henskens, Erin Kerr, Mark W Parsons, Robert W Sanson-Fisher, Christopher F Bladin, Richard I Lindley and 4 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Audit and feedback: effects on professional practice.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Christopher R LeviThe University of Newcastle, School of Medicine and Public Health Callaghan Australia.
John A AttiaThe University of Newcastle, School of Medicine and Public Health Callaghan Australia.
Cate D'EsteThe University of Newcastle, School of Medicine and Public Health Callaghan Australia.
Annika E RyanThe University of Newcastle, School of Medicine and Public Health Callaghan Australia.
Frans HenskensThe University of Newcastle, School of Medicine and Public Health Callaghan Australia.
Erin KerrHunter New England Health New Lambton Heights Australia.
Mark W ParsonsHunter New England Health New Lambton Heights Australia.
Robert W Sanson-FisherThe University of Newcastle, School of Medicine and Public Health Callaghan Australia.
Christopher F BladinEastern Health Monash University Box Hill Australia.
Richard I LindleyThe George Institute for Global Health Sydney Australia.
Sandy MiddletonNursing Research Institute Australian Catholic University and St Vincent's Health Australia Sydney and Darlinghurst Australia.
Christine L PaulThe University of Newcastle, School of Medicine and Public Health Callaghan Australia.
TIPS (Thrombolysis Implementation in Stroke) Study Group †
TIPS (Thrombolysis Implementation in Stroke) Study Group<xref ref-type="author-note" rid="jah34706-note-1002"><sup>†</sup></xref>

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute ischemic stroke is underutilized in many parts of the world. Randomized trials to test the effectiveness of thrombolysis implementation strategies are limited. Methods and Results This study aimed to test the effectiveness of a multicomponent, multidisciplinary tissue plasminogen activator implementation package in increasing the proportion of thrombolyzed cases while maintaining accepted benchmarks for low rates of intracranial hemorrhage and high rates of functional outcomes at 3 months. A cluster randomized controlled trial of 20 hospitals in the early stages of thrombolysis implementation across 3 Australian states was undertaken. Monitoring of IVT rates during the baseline period allowed hospitals (the unit of randomization) to be grouped into 3 baseline IVT strata-very low rates (0% to ≤4.0%); low rates (>4.0% to ≤10.0%); and moderate rates (>10.0%). Hospitals were randomized to an implementation package (experimental group) or usual care (control group) using a 1:1 ratio. The 16-month intervention was based on behavioral theory and analysis of the steps, roles, and barriers to rapid assessment for thrombolysis eligibility and involved comprehensive strategies addressing individual and system-level change. The primary outcome was the difference in tissue plasminogen activator proportions between the 2 groups postintervention. The absolute difference in postintervention IVT rates between intervention and control hospitals adjusted for baseline IVT rate and stratum was not significant (primary outcome rate difference=1.1% (95% CI -1.5% to 3.7%;

Indexed as

AgedAged, 80 and overAustraliaBenchmarkingBrain IschemiaFemaleFibrinolytic AgentsHumansInfusions, IntravenousMaleMiddle AgedPractice Patterns, Physicians'Quality ImprovementQuality Indicators, Health CareStrokeThrombolytic TherapyFibrinolytic AgentsTissue Plasminogen Activatorhealth system changeimplementationischemic strokequality improvementthrombolysis

Identifiers

PMID31973599
PMCPMC7033885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.